Level Four Advisory Services, LLC Amgen Inc Transaction History

Level Four Advisory Services, LLC

$2.3 Billion
Q3 2024

A detailed history of Level Four Advisory Services, LLC transactions in Amgen Inc stock. As of the latest transaction made, Level Four Advisory Services, LLC holds 13,167 shares of AMGN stock, worth $3.88 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

13,167

Previous 12,706 3.63%

Holding current value

$3.88 Million

Previous $3.97 Million 6.88%

% of portfolio

0.18%

Previous 0.19%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$309.38 - $337.38 $142,624 - $155,532	461 Added 3.63%	13,167 $4.24 Million
Q2 2024 Aug 09, 2024	BUY	$262.75 - $319.31 $2.3 Million - $2.79 Million	8,748 Added 221.02%	12,706 $3.97 Million
Q4 2023 Feb 08, 2024	BUY	$255.7 - $288.46 $25,570 - $28,845	100 Added 2.59%	3,958 $1.14 Million
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $112,386 - $139,530	-514 Reduced 11.76%	3,858 $1.04 Million
Q2 2023 Jul 10, 2023	SELL	$214.27 - $253.37 $3,428 - $4,053	-16 Reduced 0.36%	4,372 $970,000
Q1 2023 Jun 05, 2023	BUY	$225.79 - $275.2 $148,569 - $181,081	658 Added 17.64%	4,388 $1.06 Million
Q4 2022 Feb 13, 2023	BUY	$229.03 - $291.01 $136,730 - $173,732	597 Added 19.06%	3,730 $979,000
Q3 2022 Nov 07, 2022	BUY	$224.46 - $253.15 $15,487 - $17,467	69 Added 2.25%	3,133 $706,000
Q2 2022 Aug 08, 2022	SELL	$230.71 - $256.74 $45,911 - $51,091	-199 Reduced 6.1%	3,064 $745,000
Q1 2022 May 10, 2022	SELL	$219.27 - $242.57 $213,568 - $236,263	-974 Reduced 22.99%	3,263 $789,000
Q4 2021 Feb 11, 2022	BUY	$198.88 - $227.6 $466,970 - $534,404	2,348 Added 124.3%	4,237 $953,000
Q3 2021 Oct 12, 2021	SELL	$212.27 - $248.7 $489,919 - $573,999	-2,308 Reduced 54.99%	1,889 $402,000
Q2 2021 Aug 09, 2021	SELL	$233.58 - $259.14 $33,869 - $37,575	-145 Reduced 3.34%	4,197 $1.02 Million
Q1 2021 May 10, 2021	BUY	$221.91 - $258.6 $3,106 - $3,620	14 Added 0.32%	4,342 $1.08 Million
Q4 2020 Feb 10, 2021	BUY	$216.38 - $257.67 $46,305 - $55,141	214 Added 5.2%	4,328 $995,000
Q3 2020 Nov 02, 2020	SELL	$234.65 - $260.95 $181,149 - $201,453	-772 Reduced 15.8%	4,114 $1.05 Million
Q2 2020 Aug 17, 2020	BUY	$197.81 - $242.74 $966,499 - $1.19 Million	4,886 New	4,886 $1.16 Million
Q2 2020 Jul 27, 2020	SELL	$197.81 - $242.74 $868,583 - $1.07 Million	-4,391 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $25,878 - $34,321	142 Added 3.34%	4,391 $883,000
Q4 2019 Feb 13, 2020	SELL	$189.21 - $243.2 $197,156 - $253,414	-1,042 Reduced 19.69%	4,249 $1.06 Million
Q3 2019 Nov 12, 2019	SELL	$174.11 - $208.62 $243,057 - $291,233	-1,396 Reduced 20.88%	5,291 $1.02 Million
Q2 2019 Aug 14, 2019	BUY	$166.7 - $195.41 $79,015 - $92,624	474 Added 7.63%	6,687 $1.23 Million
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $98,574 - $111,114	-545 Reduced 8.06%	6,213 $1.18 Million
Q4 2018 Feb 08, 2019	SELL	$178.4 - $208.25 $36,393 - $42,483	-204 Reduced 2.93%	6,758 $1.32 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $154,346 - $174,005	-833 Reduced 10.69%	6,962 $1.44 Million
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $169,703 - $190,613	1,022 Added 15.09%	7,795 $1.44 Million
Q1 2018 May 14, 2018	SELL	$169.43 - $198.0 $23,720 - $27,720	-140 Reduced 2.03%	6,773 $1.16 Million
Q4 2017 Feb 13, 2018	BUY	$168.79 - $188.59 $314,286 - $351,154	1,862 Added 36.86%	6,913 $1.2 Million
Q3 2017 Apr 03, 2018	SELL	$167.29 - $191.0 $49,183 - $56,154	-294 Reduced 5.5%	5,051 $942,000
Q3 2017 Nov 15, 2017	BUY	$167.29 - $191.0 $128,980 - $147,261	771 Added 16.86%	5,345 $991,000
Q2 2017 Sep 20, 2017	SELL	N/A	-434 Reduced 8.67%	4,574 $742,000
Q1 2017 Sep 20, 2017	BUY	N/A	5,008	5,008 $813,000

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Level Four Advisory Services, LLC with notifications on news.

Account

Level Four Advisory Services, LLC Amgen Inc Transaction History